SEARCH
Subscribe
Track all markets on TradingView

3 Marijuana Stocks That Could Surprise on the ‘High’ Side

Published:

Reading time: 4 min.

The marijuana stocks on our list might see 75%+ earnings growth in the upcoming quarter 

SmallCapPower | January 17, 2017: There has been a frenzy of activity to capitalize on the budding marijuana sector in Canada, with Shoppers Drug Mart recently applying for a marijuana license and cannabis dispensaries sprouting up throughout the country. Today, we have identified a few high-growth marijuana stocks expected to beat earnings estimates this reporting season.

Win Big With Our Small Cap Picks

 

OrganiGram Holdings Inc. (TSX: OGI) – $2.68
Pharmaceuticals

OrganiGram Holdings Inc., formerly Inform Exploration Corp., is a Canada-based company that operates through its subsidiary Organigram Inc. Organigram Inc. is a licensed medical marijuana producer as regulated by Health Canada under the Marijuana Medical Access Regulations (MMAR) of the Government of Canada.

  • Market Cap: $270 million
  • Expected Report Date (FQ1): 27/01/2017
  • Expected Growth in EPS (FY1): 75%
  • 52-Week Total Return: +222.9%

Aurora Cannabis Inc. (TSXV: ACB) – $2.50
Marijuana

Aurora Cannabis Inc. is engaged in the production and sale of medical cannabis, as well as distributing medical marijuana pursuant to the Access to Cannabis for Medical Purposes Regulations (ACMPR). The Company’s product types include Tetrahydrocannabinol (THC), Cannabidiole (CBD), indica, sativa and hybrid. The CBD product is connected to the anti-inflammatory, pain relieving, anti-nausea, anti-anxiety and muscle relaxing functions of medical marijuana.

  • Market Cap: $714 million
  • Expected Report Date (FQ1): 28/02/2017
  • Expected Growth in EPS (FY1): 100%
  • 52-Week Total Return: +363.0%

Aphria Inc. (TSXV: APH) – $5.43
Pharmaceuticals

Aphria Inc., formerly Black Sparrow Capital Corp. is a Canada-based company, which is engaged in producing and selling medical marijuana through retail sales and wholesale channels. The Company’s retail sales are sold primarily through its online store, as well as telephone orders. Its wholesale shipments are sold to other Medical Purposes Regulations (MMPR) Licensed Producers. It offers medical cannabis of various strains, including Kusawa, Tamaracouta, Panache, Churchill and Iroquois. The Company is also engaged in the research and development, and commercial production of cannabis oil.

  • Market Cap: $609 million
  • Expected Report Date (FQ1): 19/04/2017
  • Expected Growth in EPS (FY1): 200%
  • 52-Week Total Return: +352.5%

The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.
test28919111
test28919111

Related articles

Recent articles

© SmallCapPower 2024